Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
Retrieved on:
Tuesday, December 12, 2023
“This has been a tremendous ASH meeting for Disc, as we presented data across our two most advanced programs.
Key Points:
- “This has been a tremendous ASH meeting for Disc, as we presented data across our two most advanced programs.
- “With these results and the positive initial efficacy data from the DISC-0974 myelofibrosis study that we presented earlier today, Disc is preparing to enter its next stage of growth.
- Earlier today, Disc also presented initial positive data from the ongoing phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia.
- Bitopertin and DISC-0974 are investigational agents and are not approved for use as a therapy in any jurisdiction worldwide.